Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
Plus Therapeutics (PSTV), a clinical-stage pharmaceutical company focused on targeted radiotherapeutics for central nervous system cancers, has scheduled its third quarter 2024 financial results announcement for Thursday, November 14, 2024, after market close. The management team will host a conference call and webcast at 5:00 p.m. ET to discuss the results and provide a corporate update. Participants can pre-register through the provided dial-in link and access the webcast through the company's website, where it will remain available for 90 days following the live call.
Plus Therapeutics (PSTV), un'azienda farmaceutica in fase clinica focalizzata su radioterapeutici mirati per i tumori del sistema nervoso centrale, ha programmato l'annuncio dei suoi risultati finanziari del terzo trimestre 2024 per giovedì 14 novembre 2024, dopo la chiusura del mercato. Il team di gestione ospiterà una telefonata e una webcast alle 17:00 ET per discutere i risultati e fornire un aggiornamento aziendale. I partecipanti possono preregistrarsi tramite il link di accesso fornito e accedere alla webcast attraverso il sito web dell'azienda, dove resterà disponibile per 90 giorni dopo la chiamata dal vivo.
Plus Therapeutics (PSTV), una empresa farmacéutica en etapa clínica enfocada en radioterapéuticos dirigidos para cánceres del sistema nervioso central, ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el jueves 14 de noviembre de 2024, después del cierre del mercado. El equipo de gestión realizará una llamada de conferencia y una webcast a las 5:00 p.m. ET para discutir los resultados y proporcionar una actualización corporativa. Los participantes pueden preregistrarse a través del enlace de acceso proporcionado y acceder a la webcast a través del sitio web de la empresa, donde estará disponible durante 90 días después de la llamada en vivo.
플러스 테라퓨틱스 (PSTV), 중추 신경계 암을 위한 표적 방사선 치료제에 집중하는 임상 단계 제약 회사는 2024년 3분기 재무 실적 발표를 2024년 11월 14일 목요일, 시장 폐장 후로 예정했습니다. 경영진 팀은 오후 5시(동부 표준시)에 컨퍼런스 콜과 웹캐스트를 개최하여 결과를 논의하고 기업 업데이트를 제공할 것입니다. 참가자들은 제공된 전화 접속 링크를 통해 사전 등록할 수 있으며, 회사의 웹사이트에서 웹캐스트에 접근할 수 있으며, 라이브 콜 후 90일 동안 이용 가능할 것입니다.
Plus Therapeutics (PSTV), une société pharmaceutique en phase clinique axée sur les radiothérapies ciblées pour les cancers du système nerveux central, a prévu l'annonce de ses résultats financiers du troisième trimestre 2024 pour le jeudi 14 novembre 2024, après la clôture du marché. L'équipe de direction animera une conférence téléphonique et un webinaire à 17h00 ET pour discuter des résultats et fournir une mise à jour de l'entreprise. Les participants peuvent se pré-inscrire via le lien d'accès fourni et accéder au webinaire sur le site web de l’entreprise, où il restera disponible pendant 90 jours après l'appel en direct.
Plus Therapeutics (PSTV), ein in der klinischen Phase befindliches pharmazeutisches Unternehmen, das sich auf zielgerichtete Radiotherapeutika für Krebserkrankungen des zentralen Nervensystems konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das dritte Quartal 2024 für Donnerstag, den 14. November 2024, nach Börsenschluss angesetzt. Das Management-Team wird um 17:00 Uhr ET eine Telefonkonferenz und ein Webcast durchführen, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben. Teilnehmer können sich über den bereitgestellten Einwahllink vorregistrieren und den Webcast über die Website des Unternehmens aufrufen, wo er 90 Tage nach dem Live-Call verfügbar bleiben wird.
- None.
- None.
AUSTIN, Texas, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company will report third quarter 2024 financial results on Thursday, November 14, 2024, after market close. Plus Therapeutics’ management team will then host a conference call and webcast at 5:00 p.m. ET to discuss the financial results and provide a corporate update.
Webcast and Conference Call
| Date/Time: | Thursday, November 14, 2024 @ 5:00 PM ET |
| Webcast: | https://edge.media-server.com/mmc/p/rdthweko |
| Dial-in Link: | https://register.vevent.com/register/BI0e7763782e4d40cebe225238e201e7da |
Participants are encouraged to pre-register any time before the call through the dial-in link. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company’s website under the ‘For Investors’ section. The webcast will be available on the Company’s website for 90 days following the live call.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186Re including the ability of 186Re to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of 186Re; the continued evaluation of 186Re including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Charles Y. Huang, MBA
Director of Capital Markets and Investor Relations
Office: (202)-209-5751 | Direct (301)-728-7222
chuang@plustherapeutics.com
FAQ
When will Plus Therapeutics (PSTV) release Q3 2024 earnings?
What time is Plus Therapeutics (PSTV) Q3 2024 earnings call?
How can I access Plus Therapeutics (PSTV) Q3 2024 earnings call?
